Prolytix
John Moriarity is currently serving as the Vice President of Business Development at Prolytix since January 2023. Prior to this, John held the position of Director Of Business Development at BioAgilytix from September 2020 to January 2023. John also has extensive experience as a Business Development Director at Covance for over 8 years, where John specialized in Translational Biomarkers and Companion Diagnostics. Before working at Covance, John worked as a Staff Biochemist at Merck and an Immunologist at Ortho Clinical Diagnostics. Their career started at the Centers for Disease Control and Prevention, where John worked as a Fellow, developing methodologies for DNA extraction and real-time PCR reactions. John completed their BS in Biochemistry from Kennesaw State University in 2005.
Prolytix
Prolytix, formerly Haematologic Technologies, has 30+ years of experience in protein chemistry, which ensures our team will identify and solve the challenges of your large molecule product. Our services in research and development, characterization by high-resolution mass spectrometry (HRMS), GxP testing, and custom collection devices assist clients worldwide. Using an agile, consultative approach, we support your product’s development from discovery through GMP release. With our proven CMC and regulatory expertise from IND through BLA to our accessible, attentive, and seasoned team, Prolytix is the go-to partner for protein therapeutic projects from routine to complex. For advanced protein development, go with the pro — Prolytix. To learn more about our expertise, services, and products, visit GoProlytix.com.